



**Apple juice relieves loperamide-induced constipation in rats  
by downregulating intestinal apical sodium-dependent bile  
acid transporter ASBT**

Journal:	<i>Food &amp; Function</i>
Manuscript ID	FO-ART-02-2023-000510.R1
Article Type:	Paper
Date Submitted by the Author:	08-Apr-2023
Complete List of Authors:	Zhu, Qiunan; Kanazawa University Iwai, Ryusuke; Kanazawa University Okaguchi, Takehiro; Kanazawa University Shirasaka, Yoshiyuki; Kanazawa University Tamai, Ikumi; Kanazawa University, Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences

1 **Apple juice relieves loperamide-induced constipation in rats by**  
2 **downregulating intestinal apical sodium-dependent bile acid**  
3 **transporter ASBT**

4 Qiunan Zhu <sup>a</sup>, Yusuke Iwai <sup>a</sup>, Takehiro Okaguchi <sup>a</sup>, Yoshiyuki Shirasaka <sup>a</sup>, Ikumi Tamai\*<sup>a</sup>  
5 a: Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences,  
6 Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan

7  
8 \*: Corresponding author: Ikumi Tamai, Ph.D.

9 Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences,  
10 Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi,  
11 Kanazawa 920-1192, Japan

12 Tel: +81-76-234-4479; Fax: +81-76-264-6284; Email: tamai@p.kanazawa-u.ac.jp

13

**14 Abstract**

15 Apples are known to exhibit various beneficial effects on human health. In the present study, we  
16 investigated the effect of continuous intake of apple juice (AJ) on constipation status. A single dose  
17 of loperamide in rats as the constipation model markedly decreased the weight and number of fecal  
18 pellets compared to saline-administered rats as a control. After the administration of AJ twice a day  
19 for seven days, recovery of defecation close to that of the control was observed in loperamide-  
20 treated rats. In addition, the total bile acid content in the feces increased from day 4 after the  
21 administration of AJ. Among hepatic and intestinal transporters and enzymes that regulate bile  
22 acids, the mRNA and protein expression of apical sodium-dependent bile acid transporter (asbt,  
23 *slc10a2*) was decreased by AJ in rats. Furthermore, the asbt-mediated bile acid transport activity in  
24 the rat ileum decreased after AJ administration. Moreover, in human colonic cancer-derived Caco-  
25 2 cells, AJ exposure for 24 and 48 h decreased the expression of ASBT mRNA, protein, and uptake  
26 activity of taurocholic acid in both 7- and 21-d cultures. Several components of AJ, such as  
27 procyanidins, decreased the expression of ASBT in Caco-2 cells. In conclusion, ASBT  
28 downregulation is a possible mechanism responsible for the constipation-relieving effect of apples,  
29 and procyanidins may play a role in downregulating ASBT, which leads to beneficial effects of  
30 apples against constipation. Although it is generally agreed that the common dietary compositions  
31 play a role in constipation relief, the novel specific mechanism of apples found in this study would  
32 facilitate understanding food functions.

33

## 34 1. Introduction

35 Apple is a globally popular fruit that contains polyphenols, vitamins, minerals, and dietary  
36 fibers. Apples exhibit various biological functions: intestinal transporter OATP2B1, which  
37 facilitates drug absorption such as fexofenadine is susceptible to apple juice (AJ), causing  
38 drug-food interaction<sup>1,2</sup>; apples also change the levels of various biomarkers in plasma:  
39 lowering low-density lipoprotein cholesterol<sup>3</sup>, lowering plasma triglyceride<sup>4</sup>, and improving  
40 insulin<sup>5</sup>, showing health benefits, including lowering the risk of stroke<sup>6</sup>, relieving  
41 constipation<sup>7</sup>, and others<sup>8,9</sup>. Among the various benefits, a relieving constipation has long  
42 been known.

43 Besides foods such as apples, laxatives, including stool softeners, osmotic laxatives, and  
44 stimulant laxatives, have been used for treating constipation. In 2018, GOOFICE<sup>®</sup> tablet was  
45 successfully approved as a new drug for chronic idiopathic constipation in Japan<sup>10</sup>. The  
46 active pharmaceutical ingredient (API) of GOOFICE<sup>®</sup> is elobixibat, which was developed  
47 as a selective intestinal bile acid transporter inhibitor that promotes spontaneous bowel  
48 movement and secretion of water into the gut lumen by increasing bile acid (BAs) content  
49 in the gut lumen.

50 BAs are important biological detergents produced from cholesterol in hepatocytes and  
51 are secreted into the lumen of the small intestine to facilitate the dissolution of lipids to be  
52 absorbed. The BAs are then reabsorbed from the intestine and back to the liver, while less  
53 than 10% of BAs are excreted into feces, escaping enterohepatic circulation. A series of  
54 transporters and enzymes are involved in enterohepatic circulation, among which the  
55 intestinal apical sodium-dependent bile acid transporter ASBT (*SLC10A2*, also known as  
56 iBAT, ileal bile acid transporter) is responsible for the reabsorption of BAs in the small  
57 intestine and plays a pivotal role in enterohepatic circulation to maintain homeostasis of  
58 BAs. Owing to the multiple physiological functions of BAs, including solubilizing dietary  
59 lipids<sup>11</sup> and regulating cholesterol and glucose by combining several hepatic and intestinal  
60 receptors, such as TGR5 and FXR<sup>12</sup>, ASBT dysfunction results in multiple diseases. An  
61 increase in ASBT activity may lead to progressive familial intrahepatic cholestasis<sup>13</sup>,  
62 necrotizing enterocolitis<sup>14</sup>, and diabetes mellitus<sup>15</sup>. A decrease in ASBT activity results in  
63 colonic bile acid accumulation and diarrhea<sup>16</sup>. Thus, ASBT has been receiving increasing  
64 attention as a potential drug target in recent years.

65 Depression of ASBT shows similar alterations in these biomarkers in apples: decreased  
66 low-density lipoprotein cholesterol<sup>17</sup>, decreased plasma triglyceride<sup>18</sup>, and increased  
67 insulin<sup>18</sup>. Considering the high consistency between apple intake and ASBT depression and  
68 our previous finding of decreased expression of ASBT mRNA in Caco-2 cells after exposure  
69 to apple-derived small extracellular vesicles<sup>19</sup>, we hypothesized that apples relieve  
70 constipation by altering the bile acid disposition caused by downregulation of ASBT. The  
71 present study aimed to clarify the mechanism underlying the beneficial effects of apples on  
72 constipation. We demonstrated that AJ could relieve loperamide-induced constipation by  
73 increasing fecal BAs. We then investigated the alteration of ASBT expression and ASBT-  
74 mediated transport activity in rats and Caco-2 cells. Finally, we studied the components of  
75 AJ that can depress ASBT expression.

76

## 77 2. Materials and Methods

### 78 2.1 Materials

79 The apples (Sun Fuji) were harvested from Sawaguchi Farm (Iwate, Japan). Caco-2 cells  
80 were purchased from the RIKEN Cell Bank (Tsukuba, Japan). Fluorescent bile acid, tauro-  
81 nor-THCA-24-DBD(N-(24-[7-(4-N,N-dimethylaminosulfonyl-2,1,3-  
82 benzoxadiazole)]amino-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-27-nor-5 $\beta$ -cholestan-26-oyl)-2'-  
83 aminoethanesulfonate), was purchased from GenoMembrane Co., Ltd. (Yokohama, Japan).

84 [<sup>3</sup>H]Taurocholic acid ([<sup>3</sup>H]TCA, specific activity 20 Ci/mmol) was obtained from American  
85 Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). Elobixibat was extracted using  
86 dimethylformamide from GOOFICE<sup>®</sup> tablets from EA Pharma Co., Ltd. (Tokyo, Japan).  
87 RNAiso Plus<sup>®</sup>, M-MLV reverse transcriptase, and SYBR<sup>®</sup> green qPCR master mix were  
88 obtained from Takara Bio Inc. (Shiga, Japan), Promega Corporation (Tokyo, Japan), and  
89 Agilent Technologies Japan Ltd. (Tokyo, Japan), respectively. Anti-*SLC10A2* (GTX03115)  
90 and anti-GAPDH (60004-1-Ig) antibodies were purchased from GeneTex (Irvine, CA, USA)  
91 and Cell Signaling Technology (Danvers, MA, USA), respectively. All other chemicals and  
92 reagents of the highest commercially available purity or reagent grade were obtained from  
93 FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan), Nacalai Tesque Inc. (Kyoto,  
94 Japan), Cayman Chemical (Ann Arbor, MI, USA), and Tokyo Chemical Industry Co. Ltd.  
95 (Tokyo, Japan).

## 96 2.2 Preparation of apple juice

97 Whole apples (containing skin and core) were ground with a plastic grater, and the obtained  
98 juice was centrifuged at 2,000 x g for 20 min at 4 °C to exclude debris. The supernatant was  
99 further centrifuged at 13,000 x g for 70 min at 4 °C and the supernatant was collected as AJ.

## 100 2.3 Cell culture

101 Caco-2 cells were used at passage numbers between 15 and 35, and were cultured in  
102 Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum  
103 (FBS), 0.1 mM nonessential amino acids, antibiotics benzylpenicillin (100 U/mL) and  
104 streptomycin (100 µg/mL). The cells were seeded on collagen-coated plates and cultured for  
105 7 or 21 d in a humidified incubator (5% CO<sub>2</sub>, 37 °C).

## 106 2.4 AJ treatment and preparation of constipation model in rats

107 Male Wistar rats (6–8 weeks) were purchased from Sankyo Labo Service Corp., Inc.  
108 (Toyama, Japan). All animals were allowed free access to food and water under a standard  
109 12 h light/12 h dark cycle in a temperature-controlled (23 ± 1 °C) and humidity-controlled  
110 (55 ± 5%) room until use. All animal procedures were performed in accordance with the  
111 Guidelines for Care and Use of Laboratory Animals of Kanazawa University and  
112 experiments were approved by the Animal Ethics Committee of Kanazawa University  
113 (Permit No. AP-204199).

114 AJ (or saline as control) was administrated by oral gavaging at a dose of 10 mL/kg every  
115 12 h for seven consecutive days, and loperamide or saline as control was administered  
116 intraperitoneally at a concentration of 0.3 mg/kg once at 1 h after the last administration of  
117 AJ. Feces were collected daily during AJ administration and 12 h after loperamide injection.  
118 The wet weight was measured, and water content was calculated by subtracting the dry  
119 weight measured after vacuum drying. Ethanol was then added to extract BAs. The  
120 supernatant obtained after centrifugation of the feces at 21,600 x g for 15 min at 4 °C was  
121 dried under reduced pressure. The concentration of BAs in the supernatant was measured  
122 using the total bile acid assay kit following the manufacturer's instructions (Diazyme  
123 Laboratories Inc., Poway, CA, USA).

124 For tissue collection of intestine and liver, rats were anesthetized by intraperitoneal  
125 injection of a triple anesthetic combination (medetomidine, midazolam and butorphanol)  
126 after continuous AJ administration for 7 d. The liver and intestine were washed with ice-cold  
127 phosphate-buffered saline (PBS) to remove blood and intestinal contents and collected for  
128 further gene and protein expression analyses.

## 129 2.5 *In situ* intestinal closed-loop method

130 The asbt activity in the intestine was quantified using an *in situ* closed loop of the ileum in  
131 rats, as described previously<sup>20</sup>. After free access to AJ for four days, the 24-h fasted rats were

132 anesthetized, and the intestine was exposed. Care was taken to avoid affecting the intestinal  
133 blood supply. A 10-cm loop was made at the end of the ileum segment by cannulating the  
134 tube into incisions at both ends. Warmed saline and air were flushed alternately to remove  
135 the intestinal contents. PBS (pH 6.5, 1 mL) containing tauro-nor-THCA-24-DBD (2  $\mu$ M) in  
136 the presence and absence of elobixibat (10 nM) were pushed into the loop and followed by  
137 tightening the ends of loop immediately. The intestinal solution was collected after 20 min  
138 by washing the intestine with a warmed mobile phase used for high-performance liquid  
139 chromatography (HPLC) analysis. Finally, intestinal tissues were isolated immediately to  
140 evaluate ASBT mRNA expression.

141 The entire luminal solution was collected and centrifuged at 3,000  $\times$  g for 15 min at 4  $^{\circ}$ C,  
142 and the resultant supernatant was used to quantify remaining tauro-nor-THCA-24-DBD  
143 using HPLC analysis. The quantification was performed as described previously<sup>21</sup>. To  
144 estimate the ASBT activity of the ileum, the apparent permeability coefficient ( $P_{app}$ , cm/s)  
145 was calculated using the following equation:

$$146 \quad P_{app} = (k_a \times V_d) / 2\pi r l$$

147 where  $k_a$  is the first-order absorption rate constant of tauro-THCA-24-DBD estimated from  
148 its disappearance rate during 20 min,  $V_d$  is the volume of tauro-THCA-24-DBD solution  
149 added to the closed loop (1 mL), and  $r$  and  $l$  are the radius (0.178 cm, reported by Fagerholm  
150 et al.<sup>22</sup>) and length (10 cm) of the ileum segment, respectively. Permeability was measured  
151 in the presence and absence of elobixibat, and elobixibat-sensitive permeation was regarded  
152 as ASBT-mediated permeability.

## 153 **2.6 Gene expression analysis using quantitative real-time reverse transcription-PCR (qRT- 154 PCR)**

155 For mRNA determination, total RNA was extracted from the rat intestine, rat liver, and  
156 Caco-2 cells using RNAiso Plus<sup>®</sup> and reverse-transcribed to complementary DNA using  
157 random primers and M-MLV reverse transcriptase. The obtained cDNA was used to perform  
158 quantitative real-time PCR to detect the BA-related gene expression using SYBR<sup>®</sup> Green  
159 qPCR Master Mix and the corresponding primers listed in Table 1 on an AriaMx Real-Time  
160 PCR system (Agilent Technologies, Inc.), using HPRT as an endogenous control.

## 161 **2.7 Western blotting**

162 Total protein was extracted from Caco-2 cells using M-PER<sup>™</sup> mammalian protein  
163 extraction reagent (Thermo Fisher Scientific Inc., Rockford, IL, USA) containing a 1%  
164 protease inhibitor cocktail. After determining the protein concentration using a bicinchoninic  
165 acid assay kit (FUJIFILM Wako Pure Chemical Corporation), equal amounts of protein were  
166 loaded into the wells of a 12% sodium dodecyl-sulfate polyacrylamide gel electrophoresis  
167 gel, along with a marker for electrophoresis, and then transferred to a polyvinylidene fluoride  
168 membrane on a Mini Trans-Blot<sup>®</sup> Cell (Bio-Rad Laboratories Inc., Hercules, CA, USA). The  
169 membrane was blocked with 2% skimmed milk and then was incubated with anti-*SLC10A2*  
170 antibody at 4  $^{\circ}$ C overnight following incubation with goat anti-rabbit IgG antibody at room  
171 temperature for 2 h. Protein bands were detected using Immunostaining Zeta on LAS-4000  
172 (FujiFilm Co., Ltd., Tokyo, Japan). Similarly, anti-GAPDH and goat anti-mouse IgG  
173 antibodies were used as endogenous controls for GAPDH detection.

## 174 **2.8 Uptake studies in Caco-2 cells**

175 The uptake study was performed as described previously<sup>21</sup>. The 7- or 21-d cultured Caco-2  
176 cells were incubated at 37  $^{\circ}$ C for 5 min in an uptake buffer (110 mM NaCl, 4 mM KCl, 1  
177 mM MgSO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, 10 mM HEPES, and 50 mM D-mannitol, pH 7.4, adjusted with  
178 NaOH) containing 1  $\mu$ M [<sup>3</sup>H]TCA with or without elobixibat after being washed twice with  
179 250  $\mu$ L/well of prewarmed uptake buffer, and the uptake reaction was terminated by washing  
180 the cells with ice-cold uptake buffer. Protein content was measured to calculate transport  
181 activity using Bio-Rad protein assay reagent (Bio-Rad Laboratories Inc.).

## 182 2.9 Statistical analysis

183 Data are expressed as the mean values obtained from at least three experiments with the  
184 S.E.M. Statistical analyses were performed using Student's *t*-test and results were considered  
185 statistically significant when *p* value was less than 0.05 ( $p < 0.05$ ).

186

## 187 3. Results

### 188 3.1 Effect of apple juice administration on defecation and fecal bile acids in rats

189 To study the effects of AJ on constipation, loperamide was used to induce constipation.  
190 Figure 1 shows the effects of loperamide on the number of pellets (A), wet weight (B) and  
191 water content (C) of feces, respectively. Loperamide markedly decreased the number of  
192 pellets, wet weight and water content of feces compared to the control, demonstrating the  
193 establishment of a constipation model. Under physiological conditions (in the absence of  
194 loperamide), AJ did not affect defecation. However, under constipation conditions (with  
195 loperamide), AJ caused recovery of the loperamide-induced decrease in all the pellet  
196 number, wet weight and water content of feces, suggesting that AJ relieves constipation in  
197 rats.

198 As increased fecal BAs can strengthen intestinal peristalsis, we monitored the alteration  
199 of fecal BAs after AJ administration. AJ was administered every 12 h for a week, and feces  
200 were collected every 24 h. Figure 2 shows the BAs contained in feces over 7 d. AJ  
201 administration increased the fecal BAs and the difference between AJ administration and  
202 control groups became greater with time and significant difference was observed after day 4  
203 (control group:  $0.74 \pm 0.04$   $\mu\text{mol/d}$ ; AJ group:  $2.34 \pm 0.56$   $\mu\text{mol/d}$ , 3.2 folds of control  
204 group). These results suggest that AJ facilitates fecal excretion by increasing the amount of  
205 fecal BAs.

### 206 3.2 Fecal bile acids promoting effect of apple juice by downregulating asbt expression in rats

207 Since the effect of AJ administration on fecal BAs was observed gradually, the change of  
208 expression of any factors that affect intestinal disposition of BAs was considered. We  
209 quantified mRNA expression of genes involved in BA homeostasis. As shown in Fig. 3A,  
210 AJ administration did not significantly change the expression of genes in the liver, indicating  
211 that AJ does not affect the hepatic transporters and enzymes responsible for BA handling.  
212 As shown in Fig. 3B, the expression of the genes in the ileum were not significantly changed  
213 by AJ administration, except for *asbt*. AJ downregulated the expression of *asbt* to 40%  
214 of that of the control, suggesting that an increase in fecal BAs by AJ resulted from decreased  
215 reabsorption of BAs by decreased expression of *asbt*.

### 216 3.3 Effect of apple juice on *asbt* expression and function in rats

217 The *asbt*-mediated ileal transport capability of BAs was measured to confirm that the  
218 reduction of *asbt* mRNA expression caused by AJ is associated with BA reabsorption  
219 activity. Figure 4 shows the change in *asbt* mRNA expression and intestinal membrane  
220 permeability of BAs after 4-d AJ feeding. When AJ was administered, the *asbt* mRNA  
221 expression (Fig. 4A) decreased to 51% of that of the control in a manner similar to that  
222 observed in Fig. 3B. The ileal membrane permeability of BAs was evaluated by *in situ*  
223 closed-loop method using tauro-nor-THCA-24-DBD, a fluorescence analog of taurocholic  
224 acid, and the ASBT selective inhibitor elobixibat<sup>21</sup>. As shown in Fig. 4B, AJ administration  
225 significantly decreased the *asbt*-mediated transport of tauro-nor-THCA-24-DBD to 73% of  
226 that in the control. These results suggest that increased fecal BA is explained by the impaired  
227 reabsorption of BAs by downregulation of *asbt* by AJ. Accordingly, the constipation-

228 relieving effect of apples could be explained by the increased BAs in the intestinal lumen  
229 due to the reduction of asbt expression.

### 230 3.4 Effect of apple juice on ASBT expression and transport activity in Caco-2 cells

231 To investigate whether AJ can relieve constipation by downregulating ASBT in humans,  
232 Caco-2 cells were used<sup>15, 23, 24</sup>. Seven-d cultured Caco-2 cells, a model for developing  
233 intestinal cells, and 21-d cultured Caco-2 cells, a model for human intestinal epithelium<sup>25-28</sup>,  
234 were used.

235 Figures 5A-C show the results for 7-d cultured Caco-2 cells. AJ exposure for 24 and 48  
236 h reduced ASBT mRNA expression to 51.2% and 28.3%, respectively (Fig. 5A) and protein  
237 levels to 47.8% and 45.1%, respectively (Fig. 5B). Correspondingly, the ASBT-mediated  
238 transport activity of [<sup>3</sup>H]TCA decreased to 62.9% and 37.6% after 24- and 48-h, respectively  
239 (Fig. 5C). The results for the 21-d cultured Caco-2 cells are shown in Fig. 5D-F. AJ exposure  
240 for 24 and 48 h significantly reduced ASBT mRNA expression to 61.8% and 40.0%,  
241 respectively (Fig. 5D) and protein to 81.1% and 57.6%, respectively (Fig. 5E).  
242 Correspondingly, the ASBT-mediated transport activity of [<sup>3</sup>H]TCA decreased to 76.7% and  
243 63.5% of the control after 24- or 48-h AJ exposure, respectively (Fig. 5F). Similar results in  
244 a human intestinal epithelium model and developing intestine cell model with rats indicate  
245 that AJ could relieve constipation by downregulating ASBT expression in humans.

### 246 3.5 Contribution of procyanidins to the downregulation of ASBT in Caco-2 cells

247 Furthermore, we assessed if the apple components can decrease ASBT expression in 21-d  
248 cultured Caco-2 cells. Eight polyphenols, chlorogenic acid, phloridzin, quercetin,  
249 kaempferol, catechin, (-)-epicatechin, procyanidin B1, and procyanidin B2, were used.  
250 Exposure to 50  $\mu$ M of each compound for 48 h resulted in ASBT mRNA expression of  
251 101.8%, 116.2%, 90.2%, 96.4%, 72.1%, 70.6%, 73.7%, and 72.3% of the control,  
252 respectively (Fig. 6). Procyanidins (catechin, (-)-epicatechin, procyanidin B1, and  
253 procyanidin B2) tended to decrease ASBT expression, with (-)-epicatechin showing a  
254 statistically significant decrease. When we further examined the effect of a mixture of four  
255 procyanidins (12.5  $\mu$ M each as low, 50  $\mu$ M each as high), they repressed ASBT mRNA  
256 expression to 66.3% and 54.1% of control, respectively. In addition, IC<sub>50</sub> values of AJ, (-)-  
257 epicatechin and procyanidin B2 on ASBT mRNA expression were evaluated in 21-d cultured  
258 Caco-2 cells. Concentration dependent inhibitory curves are showed in Supplemental Fig. 1,  
259 and IC<sub>50</sub> values were estimated to  $67.3 \pm 29.7 \mu$ M,  $67.0 \pm 35.2 \mu$ M and  $5.9 \pm 1.9 \mu$ M,  
260 respectively. These results suggest that procyanidins in apples contribute to decreased ASBT  
261 expression.

262

## 263 4. Discussion

264 Constipation is one of common gastrointestinal disorders with the number of patients more  
265 than 15% of population worldwide<sup>29</sup>. In constipation, the quality of life of patients declines  
266 due to symptoms such as sensation of incomplete evacuation and hard stools, in addition to  
267 reduction of bowel movement frequency. Compared with medical treatment, lifestyle  
268 modifications, such as exercise, increasing fluid intake, and increasing helpful food intake,  
269 are more acceptable, especially for the elderly and children. Apple is typically regarded as  
270 food good for alleviating constipation. In this study, ASBT downregulation was identified  
271 as a novel mechanism responsible for the constipation-relieving effects of apples.

272 In this study, the constipation-relieving effects of apples were first confirmed in rats (Fig.  
273 1). As defecation is influenced by factors other than the intestinal condition, the body weight  
274 and amount of food intake were monitored, and no significant differences were observed  
275 between the AJ and control groups, indicating that AJ relieved constipation mainly by  
276 improving the intestinal condition. Many mechanisms reported to be involved in this



277 process, such as effect of fibers, are not specific to AJ<sup>7</sup>. Therefore, we attempted to identify  
278 a specific mechanism of AJ for the defecation effect. Recently, the regulation of luminal  
279 BAs is becoming a novel treatment strategy for chronic constipation<sup>30</sup> since BAs regulate  
280 colonic motility<sup>31</sup> and water secretion<sup>32</sup>, and elobixibat was recently approved as a novel  
281 drug for treating chronic constipation by inhibiting the intestinal BA reabsorption transporter  
282 ASBT<sup>33</sup>. Accordingly, in the present study, we focused on altered bile acid enterohepatic  
283 circulation and investigated whether continuous AJ administration increases fecal BAs  
284 levels (Fig. 2). As intestinal BAs are regulated by various transporters and enzymes in the  
285 liver and small intestine, we analyzed the expression of BA-related genes (Fig. 3). BA  
286 homeostasis is regulated by enterohepatic circulation, where BAs circulate between the liver  
287 and the small intestine. In the liver, BAs are synthesized by cytochrome P450 family 7  
288 subfamily A member 1 (Cyp7a1, encoded by *Cyp7a1*) and effluxed into bile by a bile salt  
289 export pump (Bsep, encoded by *Abcb11*) and multidrug resistance-associated protein 2  
290 (Mrp2, encoded by *Abcc2*). In the ileum, BAs are reabsorbed into epithelial cells by an apical  
291 sodium-dependent bile acid transporter (Asbt, encoded by *Slc10a2*), binding to ileal bile  
292 acid-binding protein (Ibap, encoded by *Fabp6*) to be transported to the basal side of  
293 intestinal cells. In rats, BAs are effluxed out by the organic solute transporter alpha/beta  
294 (*Osta*/ $\beta$ , encoded by *Slc51a/Slc51b*) and multidrug resistance-associated protein 3 (Mrp3,  
295 encoded by *Abcc3*) into the portal vein and taken up by hepatocytes mainly by sodium  
296 taurocholate cotransporting polypeptide (Ntcp, encoded by *Slc10a1*), and by sodium-  
297 independent organic anion transporting polypeptides (Oatps), including Oatp1a1, encoded  
298 by *Slco1a1*, Oatp1a4, encoded by *Slco1a4*, and Oatp1b2, encoded by *Slco1b2*. A significant  
299 decrease in the mRNA expression of asbt by AJ in the rat ileum was observed (Fig. 3B).  
300 ASBT is responsible for the ileal reabsorption of BAs, and intestinal BA permeability was  
301 evaluated using the *in situ* closed-loop method (Fig. 4B). Since administration of AJ for 4 d  
302 was sufficient to increase the fecal BAs amount (Fig. 2), ileal BAs transport was measured  
303 after 4 d of AJ administration. Here, tauro-nor-THCA-24-DBD and elobixibat were used.  
304 Tauro-nor-THCA-24-DBD, has been previously confirmed as a useful fluorescent BA  
305 analog for ASBT evaluation<sup>21</sup> and was used to avoid contamination of endogenous BAs for  
306 evaluation; elobixibat was used to measure asbt-specific permeation in order to avoid any  
307 nonspecific permeation that could be observed as an artifact of experimental method used.  
308 To minimize the technical influence of repeated administration of AJ by gastric tubes, AJ  
309 was fed by free access. Using this procedure, AJ administration decreased asbt mRNA  
310 expression to 51% of the control (Fig. 4A), a little weaker than 7-d administration (40% of  
311 control, Fig. 3B), and ileal BAs transport activity decreased to 73% of the control, indicating  
312 that AJ decreased luminal BAs absorption by decreasing asbt expression. These results show  
313 that repeated doses of AJ suppress asbt expression, resulting in decreased reabsorption of  
314 luminal BAs and promoting defecation in a luminal BAs-dependent manner.

315 Reduced ASBT expression and BA transport activity caused by AJ were examined in  
316 human-derived intestinal Caco-2 cells (Fig. 5). Considering the effect of cell status on the  
317 regulation of transporter expression, we examined both pre- and post-differentiated Caco-2  
318 cells. Although the effect of AJ on ASBT expression in pre-differentiated cells was more  
319 noticeable than in post-differentiated cells, both exhibited essentially similar responses to AJ  
320 in downregulating ASBT expression. Differences in sensitivity to AJ may be due to lower  
321 absorption of active AJ components caused by the difference in the development of tight  
322 junctions, transporter/enzyme expression, and others<sup>34</sup>. Since the self-renewal of the  
323 intestinal epithelium takes approximately 5 d<sup>35</sup>, continuous AJ drinking for over 5 d is  
324 recommended to relieve constipation. The downregulation of ASBT by AJ is expected to be  
325 more stable and potent with time, and long-term AJ administration should be better in  
326 preventing constipation clinically.

327 Finally, we investigated the active components of AJ that downregulate ASBT. Since  
328 polyphenols are well-known active ingredients in apples, concentration of eight typical  
329 polyphenols reported in previous studies<sup>36,37</sup> are summarized (Supplemental Tab. 1) and the  
330 effect of eight typical polyphenols in AJ on ASBT expression was examined (Fig. 6). Among  
331 them, catechin, (-)-epicatechin, procyanidin B1, and procyanidin B2 tended to decrease  
332 ASBT expression, whereas (-)-epicatechin changed it significantly. These four are

333 procyanidins, and grape seed procyanidins extract was reported to suppress the expression  
334 of ASBT in human Caco-2 cells and in mice<sup>38</sup>. Furthermore, the mixture of these four  
335 procyanidins decreased ASBT expression in a concentration-dependent manner, and  
336 procyanidins in apples are thought to be responsible for suppressing ASBT mRNA  
337 expression. Moreover, IC<sub>50</sub> was estimated to 5.9 ± 1.9 % (Supplemental Fig. 1). To  
338 understand further about the inhibitory effect of procyanidins, (-)-epicatechin, which showed  
339 significantly strong inhibition on ASBT among the four, and procyanidin B2, which is  
340 contained most abundantly in AJ (Supplemental Tab. 1) were selected and their IC<sub>50</sub> values  
341 were 67.3 ± 29.7 μM, 67.0 ± 35.2 μM, respectively (Supplemental Fig. 1). All these results  
342 suggest that AJ components downregulate the expression of ASBT, leading to increased  
343 intestinal luminal BAs and promoting defecation by the action of BAs through mechanisms  
344 of facilitation of gut motility and an increase in the water content in the lumen.

345 The results of the present study suggest that the downregulation of ASBT by AJ is a  
346 mechanism by which apples ameliorate constipation. The nonspecific effects of sugar  
347 alcohols (represented by sorbitol) and soluble fibers (represented by pectin) can relieve  
348 constipation. Sorbitol retains water in the large intestine through osmotic pressure to  
349 stimulate intestinal peristalsis and exert its laxative effect<sup>39</sup>. Changed intestinal osmotic  
350 pressure by sugar alcohols decrease concentration of luminal sodium that drives ASBT  
351 transport activity. It may impress ASBT activity, but not ASBT expression. Pectin escapes  
352 degradation by gastric acid and intestinal enzymes and is fermented by gut microbiota into  
353 short-chain fatty acids to modify peristalsis movement in the colon<sup>40</sup>. However, pectin does  
354 not change the mRNA expression of ileal ASBT expression in mice<sup>41</sup>. Therefore, the  
355 downregulation of ASBT is considered a distinctly specific novel mechanism of the  
356 constipation-relieving effect of apples.

357 Moreover, four typical procyanidins in apples were found to downregulate ASBT  
358 expression. As for the effective composition of apples on constipation relief, fiber is well-  
359 known. However, its side effect has been also reported that fibers do not improve the  
360 treatment success<sup>42</sup> and FODMAPS (fermentable oligosaccharides, disaccharides,  
361 monosaccharides and polyols, a kind of high-fiber food) worsen constipation-type irritable  
362 bowel syndrome<sup>43</sup>. The finding that apple-derived procyanidins can downregulate ASBT  
363 shows that using these natural products is potential to relieve constipation, giving the  
364 possibility to improve the constipation patients' quality of life, especially for constipation-  
365 type IBS. On the other hand, the IC<sub>50</sub> values of (-)-epicatechin, procyanidin B2 and AJ were  
366 67.3 ± 29.7 μM, 67.0 ± 35.2 μM and 5.9 ± 1.9 %, respectively (Supplemental fig. 1),  
367 while 7.4 μM (-)-epicatechin and 4.3 μM procyanidin B2 in 5.9% juice are contained  
368 (Supplemental Tab. 1), indicating that contribution of these components to constipation  
369 relieving effect of apples is possible. In addition, contribution of other components cannot  
370 be excluded. Besides small molecules, large molecules such as apple-derived microRNAs  
371 may also contribute to decreased expression of ASBT, since small extracellular vesicles from  
372 apples were recently reported to downregulate several intestinal transporters including  
373 ASBT in Caco-2 cells<sup>19</sup> and one of intestinal transporters, OATP2B1, is downregulated by  
374 specific apple microRNAs contained in apple-derived small extracellular vesicles<sup>44</sup>. We are  
375 now investigating the effect of apple-derived small extracellular vesicles on ASBT  
376 expression.

377 About the alteration of intestinal luminal BAs, in addition to these gene-regulating effects  
378 in apples, the direct effect of AJ components on ASBT transport activity may also be  
379 involved because AJ inhibited the uptake of taurocholic acid by Caco-2 cells in an AJ-  
380 concentration-dependent manner with an IC<sub>50</sub> value of 61.9% ± 16.9% AJ (data not shown).  
381 As well, changes in the expression of other hepatic and intestinal BA-related genes cannot  
382 be completely excluded (Fig. 3). Apart from *asbt*, *ibabp* showed a high tendency to decline  
383 by AJ with *p* value of 0.11, followed by *mrp3*, *ostα*, and *ostβ*, whereas genes in the liver  
384 showed no differences. Changes in these intestinal transporters might be involved in the  
385 decreased reabsorption of BAs. Accordingly, AJ exposure longer than 7 d conducted in the  
386 present study may promote synthesis of BAs in the liver and increase hepatic uptake of  
387 cholesterol, thereby alleviating hyperlipidemia. In addition, more interesting modifications  
388 might occur if the time of AJ intake could be extended further.

## 389 Conclusions

390 The present study demonstrated that the beneficial effect of apples on constipation was due  
391 to reduced expression of intestinal BA reabsorption transporter ASBT, which increases  
392 intestinal luminal content of BAs, thereby promoting motility of the gut and water content,  
393 resulting in the relief of constipation. Several procyanidins contributed to ASBT  
394 downregulation. Downregulation of ASBT may explain other beneficial effect of apple  
395 intake for health. However, other mechanisms could also be considered to contribute to this  
396 effect in parallel, and further studies are needed to completely understand the complicated  
397 effects of food on intestinal function.

## 398 Author Contributions

399 Data curation: Zhu, Iwai, Okaguchi; Formal analysis: Zhu, Iwai; Visualization: Zhu;  
400 Funding acquisition: Tamai, Zhu; Supervision: Tamai, Shirasaka; Writing (original draft):  
401 Zhu; Writing (review and editing): Tamai, Shirasaka.

## 402 Conflicts of interest

403 There are no conflicts to declare.

## 404 Acknowledgements

405 This study was supported by a Grant-in-Aid for Scientific Research (B) [16H05111] (IT),  
406 Grant-in-Aid for Challenging Research (Exploratory) [20K21474] (IT) from the Japan  
407 Society for the Promotion of Science (JSPS), and JST SPRING [JPMJSP2135] (QZ) from  
408 the Japan Science and Technology Agency (JST).

## 409 References

- 410 1. I. Tamai and T. Nakanishi, OATP transporter-mediated drug absorption and interaction, *Current opinion in*  
411 *pharmacology*, 2013, **13**, 859-863.
- 412 2. I. Tamai, Oral drug delivery utilizing intestinal OATP transporters, *Advanced drug delivery reviews*, 2012, **64**,  
413 508-514.
- 414 3. Y. Nagasako-Akazome, T. Kanda, Y. Ohtake, H. Shimasaki and T. Kobayashi, Apple polyphenols influence  
415 cholesterol metabolism in healthy subjects with relatively high body mass index, *Journal of oleo science*, 2007,  
416 **56**, 417-428.
- 417 4. O. Aprikian, V. Duclos, S. Guyot, C. Besson, C. Manach, A. Bernalier, C. Morand, C. Rémésy and C. Demigné,  
418 Apple pectin and a polyphenol-rich apple concentrate are more effective together than separately on cecal  
419 fermentations and plasma lipids in rats, *The Journal of nutrition*, 2003, **133**, 1860-1865.
- 420 5. M. L. Castro-Acosta, S. G. Stone, J. E. Mok, R. K. Mhajan, C. I. Fu, G. N. Lenihan-Geels, C. P. Corpe and W. L. Hall,  
421 Apple and blackcurrant polyphenol-rich drinks decrease postprandial glucose, insulin and incretin response to  
422 a high-carbohydrate meal in healthy men and women, *The Journal of nutritional biochemistry*, 2017, **49**, 53-62.
- 423 6. D. A. Hyson, A comprehensive review of apples and apple components and their relationship to human health,  
424 *Advances in nutrition (Bethesda, Md.)*, 2011, **2**, 408-420.
- 425 7. Z. Katsirma, E. Dimidi, A. Rodriguez-Mateos and K. Whelan, Fruits and their impact on the gut microbiota, gut  
426 motility and constipation, *Food & function*, 2021, **12**, 8850-8866.
- 427 8. P. Knekt, R. Jarvinen, A. Reunanen and J. Maatela, Flavonoid intake and coronary mortality in Finland: a cohort  
428 study, *BMJ (Clinical research ed.)*, 1996, **312**, 478-481.
- 429 9. M. Conceição de Oliveira, R. Sichiari and A. Sanchez Moura, Weight loss associated with a daily intake of three  
430 apples or three pears among overweight women, *Nutrition (Burbank, Los Angeles County, Calif.)*, 2003, **19**, 253-  
431 256.
- 432 10. V. Chedid, P. Vijayvargiya and M. Camilleri, Elobixibat for the treatment of constipation, *Expert review of*  
433 *gastroenterology & hepatology*, 2018, **12**, 951-960.

- 434 11. A. F. Hofmann and K. J. Mysels, Bile salts as biological surfactants, *Colloids and Surfaces*, 1987, **30**, 145-173.
- 435 12. M. Düfer, K. Hörth, R. Wagner, B. Schittenhelm, S. Prowald, T. F. Wagner, J. Oberwinkler, R. Lukowski, F. J.
- 436 Gonzalez, P. Krippeit-Drews and G. Drews, Bile acids acutely stimulate insulin secretion of mouse  $\beta$ -cells via
- 437 farnesoid X receptor activation and K(ATP) channel inhibition, *Diabetes*, 2012, **61**, 1479-1489.
- 438 13. K. D. Setchell, C. M. Rodrigues, C. Clerici, A. Solinas, A. Morelli, C. Gartung and J. Boyer, Bile acid concentrations
- 439 in human and rat liver tissue and in hepatocyte nuclei, *Gastroenterology*, 1997, **112**, 226-235.
- 440 14. M. D. Halpern, H. Holubec, T. A. Saunders, K. Dvorak, J. A. Clark, S. M. Doelle, N. Ballatori and B. Dvorak, Bile
- 441 acids induce ileal damage during experimental necrotizing enterocolitis, *Gastroenterology*, 2006, **130**, 359-372.
- 442 15. F. Annaba, K. Ma, P. Kumar, A. K. Dudeja, R. D. Kineman, B. L. Shneider, S. Saksena, R. K. Gill and W. A. Alrefai,
- 443 Ileal apical Na<sup>+</sup>-dependent bile acid transporter ASBT is upregulated in rats with diabetes mellitus induced by
- 444 low doses of streptozotocin, *Am J Physiol Endocrinol Metab*, 2010, **299**, G898-G906.
- 445 16. J. R. Walters and S. S. Pattni, Managing bile acid diarrhoea, *Therap Adv Gastroenterol*, 2010, **3**, 349-357.
- 446 17. M. Rudling, M. Camilleri, H. Graffner, J. J. Holst and L. Rikner, Specific inhibition of bile acid transport alters
- 447 plasma lipids and GLP-1, *BMC cardiovascular disorders*, 2015, **15**, 75.
- 448 18. T. Lundåsen, E. M. Andersson, M. Snaith, H. Lindmark, J. Lundberg, A. M. Östlund-Lindqvist, B. Angelin and M.
- 449 Rudling, Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes
- 450 elevated plasma glucose levels in mice, *PloS one*, 2012, **7**, e37787.
- 451 19. D. Fujita, T. Arai, H. Komori, Y. Shirasaki, T. Wakayama, T. Nakanishi and I. Tamai, Apple-Derived Nanoparticles
- 452 Modulate Expression of Organic-Anion-Transporting Polypeptide (OATP) 2B1 in Caco-2 Cells, *Molecular*
- 453 *pharmaceutics*, 2018, **15**, 5772-5780.
- 454 20. K. Ichijo, R. Oda, M. Ishihara, R. Okada, Y. Moteki, Y. Funai, T. Horiuchi, H. Kishimoto, Y. Shirasaka and K. Inoue,
- 455 Osmolality of Orally Administered Solutions Influences Luminal Water Volume and Drug Absorption in
- 456 Intestine, *Journal of pharmaceutical sciences*, 2017, **106**, 2889-2894.
- 457 21. Q. Zhu, H. Komori, R. Imamura and I. Tamai, A Novel Fluorescence-Based Method to Evaluate Ileal Apical
- 458 Sodium-Dependent Bile Acid Transporter ASBT, *Journal of pharmaceutical sciences*, 2021, **110**, 1392-1400.
- 459 22. U. Fagerholm, A. Lindahl and H. Lennernäs, Regional intestinal permeability in rats of compounds with different
- 460 physicochemical properties and transport mechanisms, *The Journal of pharmacy and pharmacology*, 1997, **49**,
- 461 687-690.
- 462 23. C. Thomas, J. F. Landrier, D. Gaillard, J. Grober, M. C. Monnot, A. Athias and P. Besnard, Cholesterol dependent
- 463 downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression:
- 464 molecular mechanism and physiological consequences, *Gut*, 2006, **55**, 1321-1331.
- 465 24. F. Deng, K. S. Kim, J. Moon and Y. H. Bae, Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT-Mediated
- 466 Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport Flow in a Cellular
- 467 Negative Feedback Loop, *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*, 2022, **9**, e2201414.
- 468 25. S. Lopez-Escalera and A. Wellejus, Evaluation of Caco-2 and human intestinal epithelial cells as in vitro models
- 469 of colonic and small intestinal integrity, *Biochemistry and biophysics reports*, 2022, **31**, 101314.
- 470 26. E. Le Ferrec, C. Chesne, P. Artusson, D. Brayden, G. Fabre, P. Gires, F. Guillou, M. Rousset, W. Rubas and M. L.
- 471 Scarino, In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46.
- 472 European Centre for the Validation of Alternative methods, *Alternatives to laboratory animals : ATLA*, 2001,
- 473 **29**, 649-668.
- 474 27. Y. Sambuy, I. De Angelis, G. Ranaldi, M. L. Scarino, A. Stamatii and F. Zucco, The Caco-2 cell line as a model of
- 475 the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics, *Cell*
- 476 *biology and toxicology*, 2005, **21**, 1-26.
- 477 28. Y. Sambuy, S. Ferruzza, G. Ranaldi and I. De Angelis, Intestinal cell culture models: applications in toxicology
- 478 and pharmacology, *Cell biology and toxicology*, 2001, **17**, 301-317.
- 479 29. A. E. Bharucha and B. E. Lacy, Mechanisms, Evaluation, and Management of Chronic Constipation,
- 480 *Gastroenterology*, 2020, **158**, 1232-1249.e1233.
- 481 30. S. Eswaran, A. Guentner and W. D. Chey, Emerging Pharmacologic Therapies for Constipation-predominant
- 482 Irritable Bowel Syndrome and Chronic Constipation, *Journal of neurogastroenterology and motility*, 2014, **20**,
- 483 141-151.
- 484 31. A. Bajor, P. G. Gillberg and H. Abrahamsson, Bile acids: short and long term effects in the intestine, *Scandinavian*
- 485 *journal of gastroenterology*, 2010, **45**, 645-664.
- 486 32. H. S. Mekjian, S. F. Phillips and A. F. Hofmann, Colonic secretion of water and electrolytes induced by bile acids:
- 487 perfusion studies in man, *J Clin Invest*, 1971, **50**, 1569-1577.
- 488 33. M. Simrén, A. Bajor, P. G. Gillberg, M. Rudling and H. Abrahamsson, Randomised clinical trial: The ileal bile acid
- 489 transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study,
- 490 *Alimentary pharmacology & therapeutics*, 2011, **34**, 41-50.
- 491 34. N. Li, Z. Sui, Y. Liu, D. Wang, G. Ge and L. Yang, A fast screening model for drug permeability assessment based
- 492 on native small intestinal extracellular matrix, *RSC advances*, 2018, **8**, 34514-34524.
- 493 35. C. Blanpain, V. Horsley and E. Fuchs, Epithelial stem cells: turning over new leaves, *Cell*, 2007, **128**, 445-458.
- 494 36. K. Kahle, M. Kraus and E. Richling, Polyphenol profiles of apple juices, *Molecular nutrition & food research*,
- 495 2005, **49**, 797-806.

- 496 37. Y. Shirasaka, M. Shichiri, T. Mori, T. Nakanishi and I. Tamai, Major active components in grapefruit, orange, and  
497 apple juices responsible for OATP2B1-mediated drug interactions, *Journal of pharmaceutical sciences*, 2013,  
498 **102**, 280-288.
- 499 38. R. M. Heidker, G. C. Caiozzi and M. L. Ricketts, Dietary procyanidins selectively modulate intestinal farnesoid X  
500 receptor-regulated gene expression to alter enterohepatic bile acid recirculation: elucidation of a novel  
501 mechanism to reduce triglyceridemia, *Molecular nutrition & food research*, 2016, **60**, 727-736.
- 502 39. A. G. Catto-Smith, R. B. Scott, H. M. Machida and D. G. Gall, Sorbitol as a Cryptic Cause of Diarrhea, *Canadian*  
503 *Journal of Gastroenterology*, 1988, **2**, 420421.
- 504 40. A. Koutsos, K. M. Tuohy and J. A. Lovegrove, Apples and cardiovascular health--is the gut microbiota a core  
505 consideration?, *Nutrients*, 2015, **7**, 3959-3998.
- 506 41. D. Ciocan, M. Spatz, N. Trainel, K. Hardonnière, S. Domenichini, F. Mercier-Nomé, A. Desmons, L. Humbert, S.  
507 Durand, G. Kroemer, A. Lamazière, C. Hugot, G. Perlemuter and A. M. Cassard, Modulation of the Bile Acid  
508 Enterohepatic Cycle by Intestinal Microbiota Alleviates Alcohol Liver Disease, *Cells*, 2022, **11**.
- 509 42. J. Yang, H. P. Wang, L. Zhou and C. F. Xu, Effect of dietary fiber on constipation: a meta analysis, *World journal*  
510 *of gastroenterology*, 2012, **18**, 7378-7383.
- 511 43. S. S. Rao, S. Yu and A. Fedewa, Systematic review: dietary fibre and FODMAP-restricted diet in the management  
512 of constipation and irritable bowel syndrome, *Alimentary pharmacology & therapeutics*, 2015, **41**, 1256-1270.
- 513 44. H. Komori, D. Fujita, Y. Shirasaki, Q. Zhu, Y. Iwamoto, T. Nakanishi, M. Nakajima and I. Tamai, MicroRNAs in  
514 Apple-Derived Nanoparticles Modulate Intestinal Expression of Organic Anion-Transporting Peptide  
515 2B1/SLCO2B1 in Caco-2 Cells, *Drug metabolism and disposition: the biological fate of chemicals*, 2021, **49**, 803-  
516 809.
- 517  
518

519 **Table 1. Primer list for qRT-PCR.**

Gene		Primer Sequence	
		Forward (5'→3')	Reverse (5'→3')
Rat			
<i>Abcb11</i>	Bsep	GCCATTGTGCGAGATCCTAAA	TGCAGGTCCGACCCTCTCT
<i>Abcc2</i>	Mrp2	TTTTGACACAACCTCCCACAGG	CAGCGATGCCAAAGAAACAC
<i>Abcc3</i>	Mrp3	GCATTTGTGAGCAGCCAGCC	TCGTCTAAAACCAGGACACGGC
<i>Cyp7a1</i>	Cyp7a1	GAATTGCCGTGTTGGTGAGC	CCCAGGTACGGAATCAACCC
<i>Fabp6</i>	Ibap6	TCAGTTGCCTCTCTGCTGC	CTGCTGGACCTCTGTGATGA
<i>Slc10a1</i>	Ntcp	GGAGACCTTAAGGACAAGGTG	ATGCTGATGGTGCGTCTG
<i>Slc10a2</i>	Asbt	TGGCTACAGCCTTGGTTTCT	GCAAAGACGAGCTGGAAAAC
<i>Slc1a1</i>	Oatp1a1	AACCCTGAAATGTGGTCAGC	TCCTTCTCTCCGAGCATCAT
<i>Slc1a4</i>	Oatp1a4	GCCCTTTGATTGGACTTCTG	AAGGGAAAGCTGGTCAGGAT
<i>Slc1b2</i>	Oatp1b2	TGGACCAATCCTTGGCTTTA	TCCTCCTGTGACCTCTTTGG
<i>Slc51a</i>	Osta	ATTGGGCTCAGTGGAAATTG	GACCAAAGCAGCAGAACACA
<i>Slc51b</i>	Ostβ	GTTCTGGCAGTCCTGGTGAT	GCCAAGTCTGCCTTCTCTGA
<i>Hprt</i>	Hprt	GACTTTGCTTTTCTTGGTCA	GTCTGGCCTGTATCCAACAC
Human			
<i>SLC10A2</i>	ASBT	TCGACTCTGGGAGCATCGTA	CTTTTTGGGGCCATTTGTGA
<i>HPRT</i>	HPRT	TTCTTTGCTGACCTGCTGGA	CCCCTGTTGACTGGTCATTACA

520

521 **Figure legend**

522 **Figure 1.** Effect of AJ administration on loperamide-induced constipation in rats.

523 Rats were orally administered saline as vehicle or apple juice (AJ) at 10 mL/kg every 12 h  
524 for 7 d. Loperamide or saline was given intraperitoneally at a dose of 0.3 mg/kg at 1 h after  
525 the last administration of saline or AJ. Stool samples were collected at 12 h after  
526 loperamide dosing. Pellet number (A), wet weight (B) and water content (C) were  
527 measured. Median and quartiles are indicated (n=4–6). \*: Significantly different from “AJ -  
528 Loperamide -” group by Student *t*-test ( $*p<0.05$ ), †: Significantly different from “AJ -  
529 Loperamide +” group by Student *t*-test ( $†p<0.05$ )  
530

531 **Figure 2.** Effect of AJ administration on fecal bile acids excretion in rats.

532 Rats were orally administered saline (hollow circle) as vehicle or AJ (dark circle) at 10  
533 mL/kg every 12 h for 7 d. Feces were collected every 24 h and fecal total bile acids  
534 concentration was measured. Each result represents the mean  $\pm$  S.E.M. (n=4–6). \*:  
535 Significantly different from control group by Student *t*-test ( $*p<0.05$ ).  
536

537 **Figure 3.** Effect of AJ administration on bile acids-related gene expression in liver (A) and  
538 ileum (B) of rats.

539 Rats were orally administered saline as vehicle (slash-filled column presents the average,  
540 hollow circle presents each point) or AJ (black column presents the average, dark circle  
541 presents each point) at 10 mL/kg every 12 h for 7 d. Ileum and liver were collected 24 h  
542 after the last administration. mRNA expression of BA-related genes in liver (A) and ileum  
543 (B) was detected. Hprt was used as a housekeeping gene. Each result represents the mean  $\pm$   
544 S.E.M. (n=10). \*: Significantly different from control group by Student *t*-test ( $*p<0.05$ ).  
545

546 **Figure 4.** Effect of AJ administration on the expression and transport activity of ileal asbt  
547 in rats.

548 Rats were allowed free access to water (white column) as vehicle or AJ (black column) for  
549 4 d. (A) Asbt mRNA expression in ileum was detected. (B) Transport activity of asbt was  
550 studied by evaluating asbt-mediated permeability of tauro-nor-THCA-24-DBD by in situ  
551 closed ileal loop method. Each result represents the mean  $\pm$  S.E.M. (n=4). \*: Significantly  
552 different from control group by Student *t*-test ( $*p<0.05$ ).  
553

554 **Figure 5.** Effect of AJ exposure on the expression and transport activity of ASBT in Caco-  
555 2 cells.

556 The mRNA (A, D) and protein (B, E) expression and transport activity (C, F) of ASBT  
557 was evaluated in 7- (A–C) and 21-d cultured Caco-2 cells (D–F) after being exposed to  
558 water (white column) as vehicle or AJ (black column) for designed time, respectively.  
559 Transport activity of ASBT was described as ASBT-mediated uptake of [<sup>3</sup>H]TCA. Each  
560 result represents the mean  $\pm$  S.E.M. (n=3–4). \*: Significantly different from control group  
561 by Student *t*-test ( $*p<0.05$ ).  
562

563 **Figure 6.** Effect of apple-contained polyphenols on ASBT expression in Caco-2 cells.

564 ASBT mRNA expression was evaluated in 21-d cultured Caco-2 cells after being exposed  
565 to apple-contained polyphenols for 48 h. Each result represents the mean  $\pm$  S.E.M. (n=3–4).  
566 \*: Significantly different from control group by Student *t*-test ( $*p<0.05$ ).  
567  
568

569 **Text for graphical abstract**

570 The specific effect of apples on constipation is due to reduced expression of ASBT, which increases  
571 intestinal BAs, thereby promoting motility of the gut and water content, resulting in the relief of  
572 constipation.

573



Figure 1




Figure 2




Figure 3

## A) Liver



## B) Ileum




Figure 4




Figure 5




Figure 6

